Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
McKinsey
Boehringer Ingelheim
Dow
Johnson and Johnson

Last Updated: November 20, 2019

DrugPatentWatch Database Preview

VECTIBIX Drug Profile

See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for VECTIBIX

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Emory UniversityPhase 2
Tesaro, Inc.Phase 2
Academic and Community Cancer Research UnitedPhase 2

See all VECTIBIX clinical trials

Recent Litigation for VECTIBIX

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
PIECZENIK v. BAYER CORPORATION2010-05-04

See all VECTIBIX litigation

PTAB Litigation
PetitionerDate
Forty Seven, Inc.2018-01-08
Forty Seven, Inc.2016-08-08
Forty Seven, Inc.2016-08-05

See all VECTIBIX litigation

Pharmacology for VECTIBIX
Ingredient-typeAntibodies, Monoclonal
Mechanism of ActionHER1 Antagonists

Company Disclosures: US Patents for VECTIBIX

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 001 2006-09-27   Start Trial Abgenix, Inc. (Fremont, CA) 2039-02-26 RX company
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 001 2006-09-27   Start Trial Amgen Fremont Inc. (Fremont, CA) 2017-05-05 RX company
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 002 2006-09-27   Start Trial Abgenix, Inc. (Fremont, CA) 2039-02-26 RX company
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 002 2006-09-27   Start Trial Amgen Fremont Inc. (Fremont, CA) 2017-05-05 RX company
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 003 2006-09-27   Start Trial Abgenix, Inc. (Fremont, CA) 2039-02-26 RX company
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 003 2006-09-27   Start Trial Amgen Fremont Inc. (Fremont, CA) 2017-05-05 RX company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for VECTIBIX

These patents were identified by searching patent claims

Supplementary Protection Certificates for VECTIBIX

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
PA2008001,C0979246 Lithuania   Start Trial PRODUCT NAME: PANITUMUMABUM; REGISTRATION NO/DATE: EU/1/07/423/001, EU/1/07/423/002, EU/1/07/423/003 20071203
PA2008001 Lithuania   Start Trial PRODUCT NAME: PANITUMUMABUM; REGISTRATION NO/DATE: ANUM>EU/1/07/423/001-003 20071203
C00979246/01 Switzerland   Start Trial PRODUCT NAME: PANITUMUMABUM; REGISTRATION NUMBER/DATE: SWISSMEDIC 57872 14.10.2008
SPC005/2008 Ireland   Start Trial SPC005/2008: 20081105, EXPIRES: 20221202
91411 Luxembourg   Start Trial 91411, EXPIRES: 20221203
SPC/GB08/009 United Kingdom   Start Trial PRODUCT NAME: PANITUMUMAB; REGISTERED: UK EU/1/07/423/001 20071205; UK EU/1/07/423/002 20071205; UK EU/1/07/423/003 20071205
344 Finland   Start Trial
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Medtronic
Colorcon
Mallinckrodt
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.